Literature DB >> 17583568

The effect of cyclooxygenase-2 overexpression on skin carcinogenesis is context dependent.

Joyce E Rundhaug1, Amy Pavone, Eunjung Kim, Susan M Fischer.   

Abstract

The up-regulation of the inducible form of cyclooxygenase (COX-2), a central enzyme in the prostaglandin (PG) biosynthetic pathway, occurs in many epithelial tumors and has been associated with tumor cell proliferation and angiogenesis. To better understand the role of COX-2 in skin tumor development, we generated transgenic mice that overexpress COX-2 under the control of the keratin 14 promoter. We previously reported (Cancer Res. 62: 2516, 2002) that these mice, referred to as keratin 14 (K14).COX2 mice, were unexpectedly very resistant to 12-O-tetradecanoylphorbol 13-acetate (TPA) tumor promotion. The current studies were undertaken to determine the mechanism of this resistance and determine if it was restricted to TPA promotion. Transgenic and wild-type mice were subjected to a complete carcinogenesis protocol using 7,12-dimethylbenz[a]anthracene (DMBA) only, as well as a two-stage protocol using DMBA plus an unrelated tumor promoter, anthralin. In addition, the responses of transgenic and wild-type mice to TPA in terms of induction of proliferation and various down-stream mediators were examined. The TPA resistance phenotype correlated with a reduced ability to induce ornithine decarboxylase, interleukin-1alpha, and tumor necrosis factor-alpha and a reduced proliferation response. This resistance phenotype appears to be restricted to phorbol ester promotion because K14.COX2 mice developed six times more tumors than wild-type mice when anthralin was used as the tumor promoter. Additionally, K14.COX2 mice treated only with DMBA developed approximately 3.5 times more tumors than wild-type mice, suggesting that PGs have intrinsic tumor promoting activity. We conclude that the role of PGs in skin tumorigenesis is context dependent. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17583568     DOI: 10.1002/mc.20340

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  16 in total

1.  Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice.

Authors:  Jean Y Tang; Michelle Aszterbaum; Mohammad Athar; Franco Barsanti; Carol Cappola; Nini Estevez; Jennifer Hebert; Jimmy Hwang; Yefim Khaimskiy; Arianna Kim; Ying Lu; Po-Lin So; Xiuwei Tang; Michael A Kohn; Charles E McCulloch; Levy Kopelovich; David R Bickers; Ervin H Epstein
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

2.  The EP1 receptor for prostaglandin E2 promotes the development and progression of malignant murine skin tumors.

Authors:  Inok Surh; Joyce E Rundhaug; Amy Pavone; Carol Mikulec; Erika Abel; Melissa Simper; Susan M Fischer
Journal:  Mol Carcinog       Date:  2011-07-07       Impact factor: 4.784

3.  Loss of the platelet activating factor receptor in mice augments PMA-induced inflammation and cutaneous chemical carcinogenesis.

Authors:  Ravi P Sahu; Amal A Kozman; Yongxue Yao; Sonia C DaSilva; Samin Rezania; Kellie C Martel; Simon J Warren; Jeffrey B Travers; Raymond L Konger
Journal:  Carcinogenesis       Date:  2012-01-04       Impact factor: 4.944

4.  Loss of INK4a/Arf gene enhances ultraviolet radiation-induced cutaneous tumor development.

Authors:  Israr Ahmad; Purushotham Guroji; Amanda H DeBrot; Padma P Manapragada; Santosh K Katiyar; Craig A Elmets; Nabiha Yusuf
Journal:  Exp Dermatol       Date:  2017-07-09       Impact factor: 3.960

5.  Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation.

Authors:  Kausar M Ansari; Joyce E Rundhaug; Susan M Fischer
Journal:  Mol Cancer Res       Date:  2008-06       Impact factor: 5.852

6.  Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications.

Authors:  Erika L Abel; Joe M Angel; Kaoru Kiguchi; John DiGiovanni
Journal:  Nat Protoc       Date:  2009-08-27       Impact factor: 13.491

7.  Integrated proteomics identified novel activation of dynein IC2-GR-COX-1 signaling in neurofibromatosis type I (NF1) disease model cells.

Authors:  Mio Hirayama; Daiki Kobayashi; Souhei Mizuguchi; Takashi Morikawa; Megumi Nagayama; Uichi Midorikawa; Masayo M Wilson; Akiko N Nambu; Akiyasu C Yoshizawa; Shin Kawano; Norie Araki
Journal:  Mol Cell Proteomics       Date:  2013-01-28       Impact factor: 5.911

8.  Signal transduction molecules as targets for cancer prevention.

Authors:  Ann M Bode; Zigang Dong
Journal:  Sci Signal       Date:  2009-02-24       Impact factor: 8.192

9.  Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial.

Authors:  Craig A Elmets; Jaye L Viner; Alice P Pentland; Wendy Cantrell; Hui-Yi Lin; Howard Bailey; Sewon Kang; Kenneth G Linden; Michael Heffernan; Madeleine Duvic; Ellen Richmond; Boni E Elewski; Asad Umar; Walter Bell; Gary B Gordon
Journal:  J Natl Cancer Inst       Date:  2010-11-29       Impact factor: 13.506

10.  Molecular mechanisms of mouse skin tumor promotion.

Authors:  Joyce E Rundhaug; Susan M Fischer
Journal:  Cancers (Basel)       Date:  2010       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.